摘要
目的：对比替吉奥联合奥沙利铂（L-OHP）与卡培他滨联合L-OHP治疗晚期胃癌的疗效和不良反应。方法对2011年3月至2014年12月郑州人民医院收治的93例晚期胃癌患者资料进行回顾性分析。其中替吉奥联合L-OHP治疗组（SL组）48例，卡培他滨联合L-OHP治疗组（XL组）45例。SL组：给予替吉奥每天80 mg／m2，分两次口服，第1天至第14天；L-OHP 130 mg／m2，静脉滴注2 h，第1天。XL组：卡培他滨每天2000 mg／m2，分两次口服，第1天至第14天；L-OHP 130 mg／m2，静脉滴注2 h，第1天。化疗周期为21 d。完成2个周期后评估疗效和不良反应。结果SL组和XL组总有效率分别为52.08%（25／48）和53.33%（24／45），差异无统计学意义（P＞0.05）。SL组消化道不良反应发生率高于XL组[52.08%（25／48）和24.44%（11／45），P＜0.05]。SL组口腔黏膜炎发生率低于XL组[25.00%（12／48）和51.11%（23／45），P 〈0.05]。结论替吉奥联合L-OHP与卡培他滨联合L-OHP治疗晚期胃癌均安全、有效。
Objective To compare the efficacy and side effects of S-1 combined with oxaliplatin and capecitabine combined with oxaliplatin in treatment of advanced gastric cancer. Methods From Mar 2011 to Dec 2014, the data of 93 cases with gastric cancer in Zhengzhou Peopleˊs Hospital were studied retrospectively. 48 cases treated by S-1 combined with oxaliplatin （SL group） and 45 cases treated by capecitabine combined with oxaliplatin （XL group）. The patients of SL group received S-1 80 mg·m-2·d-1, bid, po, d1-14, L-OHP 130 mg/m2, ivgtt, 2 hours, d1. The patients of XL group received capecitabine 2 000 mg·m-2·d-1, bid, po, d1-14, L-OHP 130 mg/m2, ivgtt, 2 hours, d1. The course was 21 days in two groups. The efficacy and side effects were evaluated after two courses. Results The efficacy rates of SL and XL group were 52.08 % （25/48） and 53.33 % （24/45）, respectively there was no significant difference （P 〉 0.05）. The incidence rate of gastrointestinal reaction in SL group was obviously higher than that in XL group [52.08%（25/48） vs 24.44%（11/45）, P〈0.05]. The incidence rate of oral mucositis in SL group was significantly lower than that in XL group [25.00 % （12/48） vs 51.11 % （23/45）, P〈 0.05]. Conclusion Both S-1 combined with L-OHP and capecitabine combined with L-OHP for gastric cancer treatment are safe and effective.
出处
《肿瘤研究与临床》
CAS
2015年第7期442-444,共3页
Cancer Research and Clinic
基金
国家自然科学基金（81472714）
